Postmenopausal leakage of urine, how and why?

Background
Urinary incontinence (UI) among women of all ages is a common disorder. UI may have a major negative effect on quality of life and cause anxiety, depression, and decreased social involvement.


Patients and methods
A prospective cohort study was conducted that involved 100 postmenopausal women experiencing urinary leakage who attended the Department of Obstetrics and Gynecology in Al-Galaa Teaching Hospital from January 2018 to July 2018. All patients had been classified into three groups: group 1 included 30 patients experiencing postmenopausal urine leakage who were performed pelvic floor exercises (PFEs), group 2 included 30 patients experiencing postmenopausal urine leakage who had been on medications (solifenacin), and group 3 included 40 patients experiencing postmenopausal urine leakage who had been under observation and placebo treatment.


Results
Regarding day and night-time micturition, there was no statistical disparity between solifenacin and PFE groups. Regarding urge and urgency incontinence, no substantial distinction between solifenacin and PFE groups was found. However, the difference between solifenacin versus placebo and PFE versus placebo was significant.


Conclusion
The research proposed versatile 5-mg solifenacin dosing as a more reliable way to decrease symptoms of overactive bladder. Moreover, the intensity of UI, pelvic floor muscle force, and stamina were increased by PFEs.